ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2586

A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis

Peter C. Taylor1, Jenya Antonova2, Jennifer Geis3, Katharine Dilger3, David Chernoff4, Diana Abdueva3, Nancy Shadick5 and Michael Weinblatt6, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA, 3Aqtual Inc., Hayward, CA, 4Chernoff Consulting, Sausalito, CA, 5Brigham and Women's Hospital, Boston, MA, 6Harvard Medical School, Waban, MA

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, Biomarkers, Genomics and Proteomics, informatics, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 15, 2023

Title: Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the clinical feasibility of a novel blood-based assay to differentiate RA patents from healthy controls and those with other conditions, including osteoarthritis (OA) and inflammatory conditions.

Methods: We acquired plasma samples from 89 individuals meeting 2010 ACR/EULAR classification criteria for RA (89 samples), 29 healthy controls (66 samples), 12 individuals with osteoarthritis (12 samples) or 61 individuals with an inflammatory condition (62 samples; Table 1). Samples were processed via chromatin enrichment assay that enables access to tissue and disease specific genetic signatures. A machine learning algorithm (involving 5-repeat 10-fold cross-validation training and testing), trained to identify synovial signatures in blood plasma, was used to generate the probabilistic estimates for the presence and absence of RA.

For RA vs non-RA, we report the area under the curve (AUC), mean (standard deviation; SD) sensitivity, overall specificity, positive likelihood ratio and negative likelihood ratio. For comparator conditions, we report specificity alone.

Results: Table 1 describes the study sample. RA subjects were 70% seropositive, 30% seronegative, 96% biologic-naïve (Table 1).The test distinguished RA from non-RA with the following overall accuracy: AUC 0.991 (0.0007), sensitivity 90.8% (0.94%), and overall specificity 96.1% (0.64%), positive likelihood ratio 24.13 (4.495) and negative likelihood ratio 0.10 (0.001). For seronegative RA, the results included sensitivity 83.7% (2.03%), positive likelihood ratio 21.46 (3.99), and negative likelihood ratio 0.17 (0.002). In comparator groups, specificity was 80.0% (0 %) for psoriatic arthritis, 88.3% (4.56%) for osteoarthritis, 92.2% (3.04%) for psoriasis, 95.4% (4.21%) for ankylosing spondylitis, and 100% (0%) for healthy controls, Crohn’s disease, and ulcerative colitis (Table 2).

Conclusion: A novel non-invasive assay differentiated individuals with RA from healthy controls and those with other inflammatory conditions without RA with high sensitivity and overall specificity. In comparator cohorts, the assay demonstrated high specificity for all groups, including healthy controls, osteoarthritis, and other inflammatory conditions. The sensitivity was maintained in seronegative individuals. Further research is needed to confirm these results in an independent study.

Note: Both Dr. Shadick and Dr. Weinblatt are last authors.

Supporting image 1

Table 1. Sample description

Supporting image 2

Table 2. Test performance in differentiation individuals with RA from those who were healthy or had health conditions adjacent to rheumatoid arthritis


Disclosures: P. Taylor: AbbVie, 2, Biogen, 2, Eli Lilly, 2, Fresenius, 2, Galapagos, 2, 5, Gilead Sciences, 2, GSK, 2, Janssen, 2, Nordic Pharma, 2, Pfizer Inc, 2, Sanofi, 2, UCB, 2; J. Antonova: Aqtual, Inc., 2; J. Geis: Aqtual, Inc., 3, 11; K. Dilger: AQTUAL, 3, 10, 11; D. Chernoff: Aqtual, Inc., 2, Reflexion Pharma, 2, 11, SetPoint Medical, 3, 11; D. Abdueva: Aqtual, Inc., 3, 4, 8, 10, 11; N. Shadick: Abbvie, 5, AQtual, 5, Bristol-Myers Squibb(BMS), 5, Janssen, 5; M. Weinblatt: Abbvie, 2, 5, Aclaris, 2, Amgen, 2, Aqtual, 5, Bristol Myers Squibb, 2, 5, Canfite, 11, Corevitas, 2, CorEvitas, 2, Eli Lilly, 2, Gilead, 2, 2, Glaxo Smith Kline, 2, Horizon, 2, Inmedix, 11, Janssen, 5, Johnson and Johnson, 2, Pfizer, 2, Prometheus Laboratories, 2, Rani, 2, Revolo, 2, Sanofi, 2, Sci Rhom, 2, Scipher, 2, 11, Set Point, 2, UCB, 2.

To cite this abstract in AMA style:

Taylor P, Antonova J, Geis J, Dilger K, Chernoff D, Abdueva D, Shadick N, Weinblatt M. A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-novel-blood-based-assay-differentiates-seropositive-and-seronegative-rheumatoid-arthritis-from-healthy-individuals-and-those-with-other-inflammatory-diseases-or-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-blood-based-assay-differentiates-seropositive-and-seronegative-rheumatoid-arthritis-from-healthy-individuals-and-those-with-other-inflammatory-diseases-or-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology